Spaulding Clinical to Offer ADME Clinical Trial Services
Addition solidifies commitment to delivering comprehensive solutions worldwide, company says.
Spaulding Clinical, a clinical research organization (CRO), has announced the addition of ADME (absorption, distribution, metabolism, and excretion) clinical trials to its list of services. According to the company, ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body.
“With the addition of ADME studies to our suite of services plus hired staff with over 60 years combined experience in conducting these trial types, Spaulding Clinical is positioned to better support our clients in making informed decisions during drug development,” said Cassandra Erato, CEO, Spaulding Clinical. “These trials play a pivotal role in understanding the behavior and fate of a drug in the body, allowing researchers to optimize dosage, assess potential drug-drug interactions, and enhance overall drug safety profiles.”
Reference: Spaulding Clinical Expands Services to Include ADME Clinical Trials. Spaulding Clinical. June 22, 2023.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
